{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:27:54Z","timestamp":1777534074056,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06814"],"award-info":[{"award-number":["21K06814"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03028"],"award-info":[{"award-number":["21H03028"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid addiction and the opioid overdose epidemic are becoming more serious, and the development of therapeutic agents is essential for the pharmacological treatment of substance use disorders. The \u03ba-opioid receptor (KOP) is a member of the opioid receptor system that has been gaining attention as a promising molecular target for the treatment of numerous human disorders, including pain, depression, anxiety, and drug addiction. Here, we biologically and pharmacologically evaluated a novel azepane-derived ligand, NP-5497-KA, as a selective KOP agonist. NP-5497-KA had 1000-fold higher selectivity for the KOP over the \u03bc-opioid receptor (MOP), which was higher than nalfurafine (KOP\/MOP: 65-fold), and acted as a selective KOP full agonist in the 3\u2032,5\u2032-cyclic adenosine monophosphate assay. The oral administration of NP-5497-KA (1\u201310\u00a0mg\/kg) dose-dependently suppressed morphine-induced conditioned place preference in C57BL\/6\u00a0J mice, and its effects were comparable to an intraperitoneal injection of nalfurafine (1\u201310\u00a0\u03bcg\/kg). Nalfurafine (10\u00a0\u03bcg\/kg) significantly inhibited rotarod performance, whereas NP-5497-KA (10\u00a0mg\/kg) exerted no effect on rotarod performance. These results indicate that NP-5497-KA may be a novel option for the treatment of opioid use disorder with fewer side effects.<\/jats:p>","DOI":"10.1038\/s41598-023-45584-4","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T13:03:24Z","timestamp":1698152604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of the novel selective \u03ba-opioid receptor agonist NP-5497-KA on morphine-induced reward-related behaviors"],"prefix":"10.1038","volume":"13","author":[{"given":"Soichiro","family":"Ide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitake","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomio","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"45584_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1073\/pnas.94.4.1544","volume":"94","author":"I Sora","year":"1997","unstructured":"Sora, I. et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA 94, 1544\u20131549 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"45584_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0301-0082(02)00008-4","volume":"66","author":"BL Kieffer","year":"2002","unstructured":"Kieffer, B. L. & Gaveriaux-Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285\u2013306 (2002).","journal-title":"Prog. Neurobiol."},{"key":"45584_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer, A., Brantl, V., Herz, A. & Emrich, H. M. Psychotomimesis mediated by kappa opiate receptors. Science 233, 774\u2013776 (1986).","journal-title":"Science"},{"key":"45584_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","volume":"72","author":"M Ranganathan","year":"2012","unstructured":"Ranganathan, M. et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans. Biol. Psychiatry 72, 871\u2013879 (2012).","journal-title":"Biol. Psychiatry"},{"key":"45584_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00213-002-1028-z","volume":"161","author":"T Mori","year":"2002","unstructured":"Mori, T., Nomura, M., Nagase, H., Narita, M. & Suzuki, T. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacol. 161, 17\u201322 (2002).","journal-title":"Psychopharmacol."},{"key":"45584_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IJNRD.S145720","volume":"11","author":"H Kozono","year":"2018","unstructured":"Kozono, H., Yoshitani, H. & Nakano, R. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch((R)) capsules 2.5 mug) in 3762 hemodialysis patients with intractable pruritus. Int. J. Nephrol. Renovasc. Dis. 11, 9\u201324 (2018).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"45584_CR7","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","volume":"25","author":"H Kumagai","year":"2010","unstructured":"Kumagai, H. et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A phase III, randomized, double-blind, placebo-controlled study. Nephrol. Dial Transplant. 25, 1251\u20131257 (2010).","journal-title":"Nephrol. Dial Transplant."},{"key":"45584_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1358\/dot.2009.45.5.1377595","volume":"45","author":"K Nakao","year":"2009","unstructured":"Nakao, K. & Mochizuki, H. Nalfurafine hydrochloride: A new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today 45, 323\u2013329 (2009).","journal-title":"Drugs Today"},{"key":"45584_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/syn.10005","volume":"42","author":"AL Svingos","year":"2001","unstructured":"Svingos, A. L., Chavkin, C., Colago, E. E. & Pickel, V. M. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42, 185\u2013192 (2001).","journal-title":"Synapse"},{"key":"45584_CR10","doi-asserted-by":"publisher","first-page":"9333","DOI":"10.1523\/JNEUROSCI.20-24-09333.2000","volume":"20","author":"AC Thompson","year":"2000","unstructured":"Thompson, A. C. et al. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J. Neurosci. 20, 9333\u20139340 (2000).","journal-title":"J. Neurosci."},{"key":"45584_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/0028-3908(93)90026-Y","volume":"32","author":"M Funada","year":"1993","unstructured":"Funada, M., Suzuki, T., Narita, M., Misawa, M. & Nagase, H. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Neuropharmacology 32, 1315\u20131323 (1993).","journal-title":"Neuropharmacology"},{"key":"45584_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0304-3940(94)90559-2","volume":"181","author":"IM Maisonneuve","year":"1994","unstructured":"Maisonneuve, I. M., Archer, S. & Glick, S. D. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181, 57\u201360 (1994).","journal-title":"Neurosci. Lett."},{"key":"45584_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0893-133X(00)00190-1","volume":"24","author":"S Schenk","year":"2001","unstructured":"Schenk, S., Partridge, B. & Shippenberg, T. S. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology 24, 441\u2013450 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"45584_CR14","doi-asserted-by":"crossref","unstructured":"Ide, S., Iwase, N., Arai, K., Kojima, M., Ushiyama, S., Taniko, K. et al. Inhibitory effects of a novel \u03bc-opioid receptor nonpeptide antagonist, UD-030, on morphine-induced conditioned place preference. Int. J. Mol. Sci., 24 (2023).","DOI":"10.3390\/ijms24043351"},{"key":"45584_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0301-0082(98)00060-4","volume":"56","author":"TM Tzschentke","year":"1998","unstructured":"Tzschentke, T. M. Measuring reward with the conditioned place preference paradigm: A comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56, 613\u2013672 (1998).","journal-title":"Prog. Neurobiol."},{"key":"45584_CR16","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","volume":"11","author":"D Cao","year":"2020","unstructured":"Cao, D. et al. Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: Disconnect between in vitro agonist bias and in vivo pharmacological effects. ACS Chem. Neurosci. 11, 3036\u20133050 (2020).","journal-title":"ACS Chem. Neurosci."},{"issue":"55\u201367","key":"45584_CR17","volume":"172","author":"T Che","year":"2018","unstructured":"Che, T. et al. Structure of the nanobody-stabilized active state of the kappa opioid receptor. Cell 172(55\u201367), e15 (2018).","journal-title":"Cell"},{"key":"45584_CR18","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.2174\/138161281942140105165011","volume":"19","author":"H Nagase","year":"2013","unstructured":"Nagase, H. & Fujii, H. Essential structure of the kappa opioid receptor agonist nalfurafine for binding to the kappa receptor. Curr. Pharm. Des. 19, 7400\u20137414 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"45584_CR19","doi-asserted-by":"crossref","unstructured":"Faouzi, A., Varga, B. R., Majumdar, S. Biased Opioid Ligands. Molecules 2020;25.","DOI":"10.3390\/molecules25184257"},{"key":"45584_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114785","volume":"243","author":"MIH Khan","year":"2022","unstructured":"Khan, M. I. H., Sawyer, B. J., Akins, N. S. & Le, H. V. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse. Eur. J. Med. Chem. 243, 114785 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"45584_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3389\/fpsyt.2014.00170","volume":"5","author":"L Lalanne","year":"2014","unstructured":"Lalanne, L., Ayranci, G., Kieffer, B. L. & Lutz, P. E. The kappa opioid receptor: from addiction to depression, and back. Front. Psychiatry 5, 170 (2014).","journal-title":"Front. Psychiatry"},{"key":"45584_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/S0024-3205(01)00957-2","volume":"68","author":"M Tsuji","year":"2001","unstructured":"Tsuji, M. et al. The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice. Life Sci. 68, 1717\u20131725 (2001).","journal-title":"Life Sci."},{"key":"45584_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/npp.2010.137","volume":"36","author":"C Chavkin","year":"2011","unstructured":"Chavkin, C. The therapeutic potential of kappa-opioids for treatment of pain and addiction. Neuropsychopharmacology 36, 369\u2013370 (2011).","journal-title":"Neuropsychopharmacology"},{"key":"45584_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-010-1825-8","volume":"210","author":"S Wee","year":"2010","unstructured":"Wee, S. & Koob, G. F. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 210, 121\u2013135 (2010).","journal-title":"Psychopharmacology"},{"key":"45584_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5055\/jom.2016.0321","volume":"12","author":"MR Jones","year":"2016","unstructured":"Jones, M. R., Kaye, A. D., Kaye, A. J. & Urman, R. D. The emerging therapeutic roles of kappa-opioid agonists. J. Opioid. Manag. 12, 101\u2013107 (2016).","journal-title":"J. Opioid. Manag."},{"key":"45584_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1124\/jpet.118.255661","volume":"371","author":"SW Kaski","year":"2019","unstructured":"Kaski, S. W. et al. Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine. J. Pharmacol. Exp. Ther. 371, 487\u2013499 (2019).","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45584-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T03:16:38Z","timestamp":1700450198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45584"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45584-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NP-5497-KA is a compound that was developed by Nippon Chemiphar\u00a0Co., Ltd., to which some of the authors belong. Nippon Chemiphar\u00a0Co., Ltd. has a patent WO2021065898A1 and partially funded this research. Other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18164"}}